Prazosin

Generic Name: Prazosin

Brand Names: Minipress, Minizide

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₁N_₅O_₄

CAS Number: 19216-56-9

Unique Ingredient Identifier: XM03YJ541D

Background: Prazosin is a drug used to treat hypertension. Prazosin is marketed by Pfizer and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists.

Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares.

Indication: This drug is indicated for the treatment of hypertension (high blood pressure). Prazosin can be given alone or given with other blood pressure-lowering drugs, including diuretics or beta-adrenergic blocking agents .
...

Associated Conditions: Agitation, Benign Prostatic Hyperplasia (BPH), Hypertension, Raynaud's Phenomenon, Disturbed sleep/nightmares

Associated Therapies: -

Clinical Trials

Prazosin for Smoking Cessation

Phase 2

Terminated

Conditions: Nicotine Dependence

Interventions: Drug: Prazosin
Drug: Placebo

First Posted Date: 2012-07-17

Last Posted Date: 2015-07-16

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 1

Registration Number: NCT01642433

Locations: 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Neurobiology of Sleep and Sleep Treatment Response in Returning Veterans

Not Applicable

Completed

Conditions: Non PTSD
PTSD

Interventions: Drug: Placebo
Drug: Prazosin

First Posted Date: 2012-07-11

Last Posted Date: 2017-05-23

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 40

Registration Number: NCT01637584

Locations: 🇺🇸
Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States

Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder

Phase 2

Completed

Conditions: Posttraumatic Stress Disorder
Alcohol Abuse

Interventions: Drug: Placebo medication
Drug: Prazosin

First Posted Date: 2012-01-26

Last Posted Date: 2020-08-25

Lead Sponsor: Seattle Institute for Biomedical and Clinical Research

Target Recruit Count: 30

Registration Number: NCT01518972

Locations: 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States

Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin

Phase 2

Completed

Conditions: Continuous Methamphetamine Abuse

Interventions: Drug: Prazosin

First Posted Date: 2010-08-09

Last Posted Date: 2016-12-30

Lead Sponsor: University of Arkansas

Target Recruit Count: 24

Registration Number: NCT01178138

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease

Not Applicable

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: Prazosin

First Posted Date: 2010-05-19

Last Posted Date: 2015-05-21

Lead Sponsor: Seattle Institute for Biomedical and Clinical Research

Target Recruit Count: 20

Registration Number: NCT01126099

Locations: 🇺🇸
Veterans Affairs Puget Sound Health Care System, Seattle, Washington, United States

Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).

Phase 3

Completed

Conditions: Alcohol Dependence
Stress Disorders, Post-Traumatic

Interventions: Drug: Prazosin
Drug: Placebo

First Posted Date: 2008-08-29

Last Posted Date: 2020-03-19

Lead Sponsor: Yale University

Target Recruit Count: 96

Registration Number: NCT00744055

Locations: 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

Alfuzosin for Medical Expulsion Therapy of Ureteral Stones

Phase 3

Conditions: Kidney Stones

Interventions: Drug: Alfuzosin
Drug: nifedipine
Drug: doxazosin
Drug: prazosin

First Posted Date: 2008-07-11

Last Posted Date: 2012-04-27

Lead Sponsor: United States Naval Medical Center, San Diego

Target Recruit Count: 240

Registration Number: NCT00713739

Locations: 🇺🇸
Naval Medical Center San Diego, San Diego, California, United States

Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction

Phase 1

Conditions: Neurogenic Bladder

Interventions: Drug: tamsolusin
Drug: prazosin

First Posted Date: 2008-01-28

Last Posted Date: 2008-01-29

Lead Sponsor: Tabriz University

Target Recruit Count: 80

Registration Number: NCT00602186

Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD

Phase 3

Completed

Conditions: PTSD
Sleep Disorders

Interventions: Drug: prazosin
Other: placebo

First Posted Date: 2007-09-20

Last Posted Date: 2018-05-01

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 304

Registration Number: NCT00532493

Locations: 🇺🇸
New York Harbor HCS, New York, New York, United States
🇺🇸
Salisbury VAMC, Salisbury, North Carolina, United States
🇺🇸
VA Medical Center, Loma Linda, Loma Linda, California, United States

and more 12 locations

Secondary Prophylaxis After Variceal Bleeding in Non-Responders

Phase 4

Completed

Conditions: Gastrointestinal Hemorrhage
Portal Hypertension
Cirrhosis

First Posted Date: 2007-03-21

Last Posted Date: 2007-03-21

Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Target Recruit Count: 50

Registration Number: NCT00450164

Locations: 🇪🇸
Unidad de Sangrantes, HSCSP, Barcelona, Spain

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy